WILLOW BIOSCIENCES ANNOUNCES APPOINTMENT OF SENIOR VICE PRESIDENT, SALES AND MARKETING

Calgary, Alberta – June 22, 2020 – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF) is pleased to announce that Christopher Speed has joined the Company as Senior Vice President, Sales and Marketing, effective July 1, 2020. In this role, Mr. Speed will lead the sales and marketing of Willow’s new line of cannabinoids, along with the Company’s strategic planning and customer initiatives.

Mr. Speed has extensive experience and knowledge of the factors that influence food, nutrition and health decisions and the consequences of these on the end-consumer. His expertise in global sales, marketing and public relations tactics, combined with a background in biochemical nutrition, is perfectly suited to advancing Willow’s business strategy. Most recently, Mr. Speed was Global Vice President of Consumer Product Goods at an industry-leading cannabinoid ingredient and solutions provider to pharmaceutical and consumer products companies. Prior to that, he was Global Senior Vice President of Sales and Marketing at a world-renowned vitamin research and development firm.

Trevor Peters, President and Chief Executive Officer of Willow, commented, “We are very excited to have Chris join our team. His expertise and experience in sales and marketing along with his strong background in the ingredients space with consumer packaged goods will be an invaluable asset as we transition Willow into a customer-focused Company.”

In his most recent roles, Chris has successfully grown sales and significantly increased the awareness of his companies’ products. This success includes gaining strong interest from global consumer packaged goods companies in the emerging commercialization of cannabinoids (both cannabidiol and several other cannabinoids that Willow is currently advancing production processes for). During his career, Chris has launched global finished brands, including Minami Nutrition and Wiley’s Finest, and has over a decade of experience working with leading CPG and ingredient brands in the natural food industry. Chris has developed a strong ability to work with a broad range of industry stakeholders to ensure the relevance to his ingredients is appreciated and that he can play a part in helping mature the market for his products.

Chris holds a Master of Human Nutrition and Dietetics from Sydney University in the behavioral and nutritional theory of human health and the impact of food/nutrition and a Bachelor of Science from the Australian National University in nutritional biochemistry, chemistry, biology, physiology and anatomy.

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company based in Calgary, Alberta, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs.

For further information, please contact:

Trevor Peters

President and Chief Executive Officer

T: (403) 669-4848

E: t.peters@willowbio.com Troy Talkkari, CFA

Vice President, Corporate Development

T: (403) 618-1117

E: t.talkkari@willowbio.com 3655 36th Street NW

Calgary, AB T2L 1Y8

Forward-Looking Statements

This news release may include forward-looking statements including opinions, assumptions, estimates and the Company’s assessment of future plans and operations, and, more particularly, statements concerning the benefits of new management additions and the business plan of the Company, generally, including cannabinoid research and production. When used in this news release, the words “will,” “anticipate,” “believe,” “estimate,” “expect,” “intent,” “may,” “project,” “should,” and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow’s products; and the successful implementation of Willow’s production and commercialization strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, risks associated with: the cannabinoid industry in general; the success of the Company’s research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; import/export and research restrictions for cannabinoid-based operations; the size of the medical-use and adult-use cannabinoid market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; adverse global events and public-health crises, including the current COVID-19 outbreak; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the AIF and the MD&A for additional risk factors relating to Willow, which can be accessed either on Willow’s website at www.willowbio.com or under the Company’s profile on www.sedar.com.

The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

News

Latest news, media & events

17/01/2023

WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT

Represents early progress against targeted milestones anticipated for 2023 to expand company growth Calgary,...
14/12/2022

WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH

Calgary, Alberta and Mountain View, California – December 14, 2022 – Willow Biosciences Inc.("Willow"...
07/12/2022

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Calgary, Alberta and Mountain View, California – December 7, 2022 – Willow Biosciences Inc.("Willow")...
08/11/2022

KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION

Kalamazoo, Michigan, Calgary, Alberta and Mountain View, California – November 8, 2022 – Willow Biosciences...
07/11/2022

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Calgary, Alberta and Mountain View, California – November 7, 2022 – Willow Biosciences Inc. ("Willow" or...
03/11/2022

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO

Calgary, Alberta and Mountain View, California – November 3, 2022 – Willow Biosciences Inc. ("Willow" or...
12/10/2022

WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO

Calgary, Alberta and Mountain View, California – October 12, 2022 – Willow Biosciences Inc. ("Willow" or...
31/08/2022

WILLOW BIOSCIENCES PROVIDES CBG UPDATE

Calgary, Alberta and Mountain View, California – August 31, 2022 – Willow Biosciences Inc. ("Willow"...
15/08/2022

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS

Calgary, Alberta and Mountain View, California – August 15, 2022 – Willow Biosciences Inc. ("Willow" or...
18/07/2022

WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO

Calgary, Alberta and Mountain View, California – July 18, 2022 – Willow Biosciences Inc. ("Willow" or...
06/06/2022

WILLOW BIOSCIENCES INCORPORATES INSCRIPTA’S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT

Calgary, Alberta and Mountain View, California – June 6, 2022 – Willow Biosciences Inc. ("Willow" or...
31/05/2022

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Calgary, Alberta and Mountain View, California – May 31, 2022 – Willow Biosciences Inc. ("Willow"...
12/05/2022

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS

Vancouver, British Columbia – May 12, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
11/05/2022

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION

Vancouver, British Columbia – May 11, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
30/03/2022

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE

Vancouver, British Columbia – March 29, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
31/01/2022

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Vancouver, British Columbia – January 31, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/01/2022

WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE

Vancouver, British Columbia – January 19, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
15/11/2021

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2021 RESULTS

Vancouver, British Columbia – November 15, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
21/09/2021

WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL SCALE OPERATIONAL UPDATE, CBGA PRODUCTION UPDATE AND CORPORATE UPDATE

Vancouver, British Columbia – September 21, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
09/08/2021

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2021 RESULTS

Vancouver, British Columbia – August 9, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
20/07/2021

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS COMMERCIAL OPERATIONS TEAM AND DEVELOPMENT PORTFOLIO, AN UPDATE ON ITS INTELLECTUAL PROPERTY POSITION, AND FORMATION OF ESG COMMITTEE

ancouver, British Columbia – July 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
10/06/2021

WILLOW BIOSCIENCES AND CELLULAR GOODS ANNOUNCE MULTIYEAR SUPPLY AGREEMENT FOR CANNABIGEROL (CBG)

Vancouver, British Columbia – June 10, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
25/05/2021

WILLOW BIOSCIENCES ANNOUNCES PARTICIPATION IN SYNBIOBETA PANEL DISCUSSION

Vancouver, British Columbia – May 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
18/05/2021

WILLOW BIOSCIENCES ADDED TO NYSE-LISTED CANNABIS ETF “THCX”

Vancouver, British Columbia – May 18, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
07/05/2021

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2021 RESULTS, AN OPERATIONAL UPDATE AND THE ADDITION OF A NEW BOARD MEMBER

Vancouver, British Columbia – May 7, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
28/04/2021

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Vancouver, British Columbia – April 28, 2021 – Willow Biosciences Inc. ("Willow" or "the Company")...
20/04/2021

WILLOW BIOSCIENCES ANNOUNCES GROUND-BREAKING SCIENTIFIC DATA FOR CANNABIGEROL (CBG) ON HUMAN SKIN

Vancouver, British Columbia – April 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
31/03/2021

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF ITS FIRST COMMERCIAL SCALE FERMENTATION RUN

Vancouver, British Columbia – March 31, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
24/03/2021

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2020 YEAR END RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – March 23, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
03/03/2021

WILLOW BIOSCIENCES PROVIDES UPDATE ON ACCELERATION OF EXPIRY DATE OF OUTSTANDING WARRANTS ISSUED PURSUANT TO OCTOBER 2020 UNIT FINANCING

Vancouver, British Columbia – March 3, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/02/2021

WILLOW BIOSCIENCES ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION AND COMPLETION OF PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING

Vancouver, British Columbia – February 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
11/02/2021

WILLOW BIOSCIENCES ANNOUNCES INCREASE TO BOUGHT DEAL OFFERING FROM $20.0 MILLION TO $25.0 MILLION

Vancouver, British Columbia – Feb. 11, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
26/01/2021

WILLOW BIOSCIENCES ANNOUNCES ACCELERATION OF EXPIRY DATE OF OUTSTANDING WARRANTS ISSUED PURSUANT TO OCTOBER 2020 UNIT FINANCING

Vancouver, British Columbia – January 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/01/2021

WILLOW BIOSCIENCES ADVANCES ITS WORK ON THC; PLANS TO LAUNCH IN THE CANADIAN MARKET

Vancouver, British Columbia – January 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
13/01/2021

WILLOW BIOSCIENCES PROVIDES UPDATE ON CANNABIGEROL RESEARCH STUDIES AND KEY PERSONNEL APPOINTMENT

Vancouver, British Columbia – January 13, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
16/12/2020

WILLOW BIOSCIENCES ADVANCES ITS COMMERICALIZATION PLAN; FIRST COMMERCIAL PRODUCTION EXPECTED IN EARLY 2021

Leading manufacturer contracted for commercial cannabinoid production • First commercial quantities of ultra-pure CBG...
13/11/2020

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2020 RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – November 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
21/10/2020

WILLOW BIOSCIENCES ANNOUNCES PRICING AND UPSIZE OF PREVIOUSLY ANNOUNCED PUBLIC OFFERING TO $10.0 MILLION

Vancouver, British Columbia – October 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
20/10/2020

WILLOW BIOSCIENCES ANNOUNCES OVERNIGHT MARKETED PUBLIC OFFERING FOR PROCEEDS OF APPROXIMATELY $8.0 MILLION

Vancouver, British Columbia – October 20, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
08/10/2020

WILLOW BIOSCIENCES PARTNERS WITH RESEARCHERS AT THE UNIVERSITY OF LETHBRIDGE AND UNIVERSITY OF CALGARY TO STUDY EFFECTS OF NON-PSYCHOACTIVE CANNABINOIDS ON PAIN, INFLAMMATION AND DEPRESSION

Vancouver, British Columbia – October 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
21/09/2020

WILLOW BIOSCIENCES ANNOUNCES SUCCESSFUL PRODUCTION OF PURE CANNABIGEROL

Vancouver, British Columbia – Sept 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
08/09/2020

WILLOW BIOSCIENCES ANNOUNCES RESEARCH AND DEVELOPMENT FUNDING FOR ITS VARIN CANNABINOIDS

Vancouver, British Columbia – September 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
12/08/2020

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2020 RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – August 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
29/07/2020

WILLOW BIOSCIENCES ANNOUNCES IT HAS COMMENCED ITS PILOT TO PRODUCE ITS FIRST CANNABINOID

Vancouver, British Columbia – July 29, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
06/07/2020

Willow Biosciences Inc. to Webcast Live at VirtualInvestorConferences.com July 9th

Company invites individual and institutional investors, as well as advisors and analysts, to attend...
22/06/2020

WILLOW BIOSCIENCES ANNOUNCES APPOINTMENT OF SENIOR VICE PRESIDENT, SALES AND MARKETING

Calgary, Alberta – June 22, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
17/06/2020

WILLOW BIOSCIENCES ANNOUNCES EXPEDITED PILOT PRODUCTION AND ADDS MULTIPLE NEW CANNABINOIDS TO PORTFOLIO

Calgary, Alberta – June 17, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
14/05/2020

Willow Biosciences Reports First Quarter 2020 Results and Provides Operations Update

Calgary, Alberta – May 14, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
09/04/2020

Willow Biosciences Announces Changes To Its Management Team

Calgary, Alberta – April 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
24/03/2020

Willow Biosciences Reports Fourth Quarter And 2019 Year End Results And Operational Update

Calgary, Alberta – March 24, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
12/03/2020

Willow Biosciences Announces Cannabinoid Scale-up And Expedited Path To Commercialization

Calgary, Alberta – March 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
07/02/2020

Willow Biosciences Improves Governance With Appointment Of Independent Chairman

Calgary, Alberta – February 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
03/12/2019

Willow Biosciences Comments on Descheduling of Partner’s Cannabidiol by U.S. Drug Enforcement Agency

Calgary, Alberta, December 3, 2019 – Willow Biosciences Inc.("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF),...
25/11/2019

Willow Biosciences Receives Conditional Approval to List on the Toronto Stock Exchange

CALGARY, November 25, 2019 – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW;...
21/11/2019

Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update

CALGARY, Nov. 21, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE:...
05/11/2019

Willow Biosciences To Commence Trading on The OTCQB® Venture Market

CALGARY, Alberta, November 5, 2019 — Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:WLLW;...
29/08/2019

Willow Biosciences Reports Second Quarter 2019 Results And Provides Operations Update

Calgary, Alberta – August 29, 2019 – Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:...
04/06/2019

Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol

New activity will add options and potential for cost savings to Noramco’s robust CBD...
27/05/2019

Willow Biosciences and Tuatara Capital Announce Exercise of Warrants

CALGARY, May 27, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE:...
14/05/2019

Willow Biosciences Inc. Announces Share Consolidation

CALGARY, May 14, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW)...
12/04/2019

Makena Resources Inc., Biocan Technologies Inc. and Epimeron Inc. Announce Completion of Private Placement, Strategic Investment From Tuatara Capital and Business Combination to Form Willow Biosciences Inc.

VANCOUVER and CALGARY, April 12, 2019 /CNW/ – Makena Resources Inc. (“Makena“) (CSE: MKNA),...

Mountain View, CA

Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.